Shots:

• Viatris’ biosimilar Semglee injection and Insulin injection will be listed on its national formularies as part of the pharmacy benefit. The biosimilar is co-developed with Biocon
• The decision follows the US FDA’s approval of the first interchangeable biosimilar insulin product through the interchangeable pathway. Both products will be available in pen and vial presentations and are interchangeable for Lantus
• The company has launched MedDrive medical drug management solutions to focus on drug savings strategies through greater biosimilar drug adoption while other elements of MedDrive include benefit designs, enhancements to predictive data analytics, medical sourcing opportunities, and consultation services

to­ / article | Ref: Prime TherapeuticsImage: LinkedIn